Yield10 Bioscience, Inc (MBLX) saw its loss narrow to $1.93 million, or $0.07 a share for the quarter ended Dec. 31, 2016. In the previous year period, the company reported a loss of $5.92 million, or $0.22 a share.

Revenue during the quarter surged 237.62 percent to $0.34 million from $0.10 million in the previous year period.

Operating loss for the quarter was $1.59 million, compared with an operating loss of $3.10 million in the previous year period.

"In 2016, we launched the business around the mission of Yield10 Bioscience to develop new technologies to produce step-change increases in crop yield,” commented Oliver Peoples, Ph.D. president and chief executive officer. "We streamlined our organizational footprint and expense structure while keeping the talent and capabilities in place to take the business forward successfully as an agricultural science company. Recently, we also made selective additions to our senior R&D staff and board of directors with individuals possessing relevant agricultural industry experience."

Cash flow from investing activities was $9.75 million from investing activities during the year as against cash outgo of $0.61 million in the last year.

Cash and cash equivalents stood at $7.31 million as on Dec. 31, 2016, down 40.43 percent or $4.96 million from $12.27 million on Dec. 31, 2015.

Working capital drops significantly
Yield10 Bioscience, Inc has witnessed a decline in the working capital over the last year. It stood at $5.10 million as at Dec. 31, 2016, down 53.36 percent or $5.84 million from $10.94 million on Dec. 31, 2015. Current ratio was at 2.85 as on Dec. 31, 2016, down from 3.80 on Dec. 31, 2015.